EN | SE Contact us Careers
1907 Tech Platforms

Technology platforms

The unique development tool F.I.R.S.T™, where patient material is the foundation throughout the development process, simultaneously identifies the clinically most relevant targets in a disease model and matching antibodies. The proprietary antibody library n-CoDeR® contains antibodies that bind specifically and strongly to their targets.


The development tool F.I.R.S.T™

BioInvent has developed a patented screening tool called F.I.R.S.T™, which is an important technical tool for internal drug development as well as for external development partners. The platform is patient-centred and facilitates the development of new antibody therapies, as new drug candidates can be produced without detailed knowledge of the antibodies’ target proteins. This unique method has the advantage of simultaneously identifying diseaseassociated targets and antibodies that bind to them.



The method makes it possible to simultaneously investigate antibody binding to both diseased and healthy tissue in order to select those antibodies and targets that are unique to diseased tissue in terms of binding and expression. Through functional, high-capacity screening, antibodies are then selected on the basis of, for example, their ability to induce cell death of primary cancer cells or improve the immune system’s capacity to eliminate tumor cells.

1907 Tech N Coder


The n-CoDeR® antibody library

BioInvent’s antibody library n-CoDeR® contains more than 30 billion human antibody genes stored within phages in test tubes. These act as production units for various antibodies, making it possible to search the library to identify precisely those antibodies that bind to a specific target protein. The n-CoDeR® library is searched using an established technology called phage display. To identify an optimal antibody, BioInvent has developed automated processes in which robots carry out the analysis on an industrial scale. The n-CoDeR® library consists of naturally occurring human antibody genes. Every component comes from nature, but the combinations are largely new, making it possible to build an antibody repertoire that is greater than nature’s own variability. BioInvent calls this “evolution beyond nature”.

 Intellectual property

Patent protection is an important component of all projects. BioInvent owns and has licenses to a global patent portfolio relating to its product pipeline, including different antibodies and therapeutic uses thereof, and to the F.I.R.S.T™ technology platform. Know-how concerning products and technologies constitutes another important intellectual property asset of BioInvent. BioInvent further owns selected trademarks.